The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma

Dave Singh, Frank Petavy, Alex J Macdonald, Aili L Lazaar, Brian J O'Connor, Dave Singh, Frank Petavy, Alex J Macdonald, Aili L Lazaar, Brian J O'Connor

Abstract

GSK256066 is a selective phosphodiesterase 4 inhibitor that can be given by inhalation, minimising the potential for side effects. We evaluated the effects of GSK256066 on airway responses to allergen challenge in mild asthmatics.

Methods: In a randomised, double blind, cross-over study, 24 steroid naive atopic asthmatics with both early (EAR) and late (LAR) responses to inhaled allergen received inhaled GSK256066 87.5 mcg once per day and placebo for 7 days, followed by allergen challenge. Methacholine reactivity was measured 24 h post-allergen. Plasma pharmacokinetics were measured. The primary endpoint was the effect on LAR.

Results: GSK256066 significantly reduced the LAR, attenuating the fall in minimum and weighted mean FEV1 by 26.2% (p = 0.007) and 34.3% (p = 0.005) respectively compared to placebo. GSK256066 significantly reduced the EAR, inhibiting the fall in minimum and weighted mean FEV1 by 40.9% (p = 0.014) and 57.2% (p = 0.014) respectively compared to placebo. There was no effect on pre-allergen FEV1 or methacholine reactivity post allergen. GSK256066 was well tolerated, with low systemic exposure; plasma levels were not measurable after 4 hours in the majority of subjects.

Conclusions: GSK256066 demonstrated a protective effect on the EAR and LAR. This is the first inhaled PDE4 inhibitor to show therapeutic potential in asthma.

Trial registration: ClinicalTrials.gov NCT00380354.

Figures

Figure 1
Figure 1
Flow chart showing study design. FeNO denotes exhaled nitric oxide. Allergen = inhaled allergen challenge. Methacholine = inhaled methacholine challenge.
Figure 2
Figure 2
Flow chart showing withdrawal of subjects during the study.
Figure 3
Figure 3
Early and late asthmatic response to inhaled allergen challenge after 7 days treatment with either GSK256066 or placebo. Means and 95% confidence intervals of change in FEV1 compared to post saline value shown.
Figure 4
Figure 4
Plot of individual derived plasma PK parameters AUC(0-t) and Cmax for GSK256066 on days 1 and 7. Summary Box and Whisker plot overlaid. Open squares represent individual values. Central line, box and whisker limits represent median, interquartile range and most extreme value with 1.5× interquartile range, respectively.

References

    1. Global strategy for asthma management and prevention. Last updated 2007.
    1. Partridge MR, Molen T van der, Myrseth SE, Busse WW. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med. 2006;6:13. doi: 10.1186/1471-2466-6-13.
    1. Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, Pedersen SE. Can guideline defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med. 2004;170:836–844. doi: 10.1164/rccm.200401-033OC.
    1. Schudt C, Gantner F, Tenors H, Hatzelmann A. Therapeutic potential of selective PDE inhibitors in asthma. Pulm Pharmacol Ther. 1999;12:123–9. doi: 10.1006/pupt.1999.0182.
    1. Spina D. PDE4 inhibitors: current status. Br J Pharmacol. 2008;155:308–15. doi: 10.1038/bjp.2008.307.
    1. Boswell-Smith V, Cazzola M, Page CP. Are phosphodiesterase 4 inhibitors just more theophylline? J Allergy Clin Immunol. 2006;117:1237–43. doi: 10.1016/j.jaci.2006.02.045.
    1. Sessler CN. Theophylline toxicity: clinical features of 116 consecutive cases. Am J Med. 1990;88(6):567–76. doi: 10.1016/0002-9343(90)90519-J.
    1. Torphy TJ. Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. Am J Respir Crit Care Med. 1998;157:351–70.
    1. Underwood DC, Osborn RT, Novak LB, Matthews JK, Newsholme SJ, Undem BJ, Hand JM, Torphy TJ. Inhibition of antigen induced bronchoconstriction and eosinophil infiltration in the guinea pig by the cyclic AMP specific phosphodiesterase inhibtor, rolipram. J Pharmacol Exp Ther. 1993;266:306–313.
    1. Bundschuh DS, Eltze M, Barsig J, Wollin L, Hatzelmann A, Beume R. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor. J Pharmacol Exp Ther. 2001;297:280–90.
    1. Harbinson PL, MacLeod D, Hawksworth R, O'Toole S, Sullivan PJ, Heath P, Kilfeather S, Page CP, Costello J, Holgate ST, Lee TH. The effect of a novel orally active selective PDE4 isoenzyme inhibitor (CDP840) on allergen-induced responses in asthmatic subjects. Eur Respir J. 1997;10:1008–14. doi: 10.1183/09031936.97.10051008.
    1. van Schalkwyk E, Strydom K, Williams Z, Venter L, Leichtl S, Schmid-Wirlitsch C, Bredenbröker D, Bardin PG. Roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, attenuates allergen-induced asthmatic reactions. J Allergy Clin Immunol. 2005;116:292–8. doi: 10.1016/j.jaci.2005.04.023.
    1. Timmer W, Leclerc V, Birraux G, Neuhäuser M, Hatzelmann A, Bethke T, Wurst W. The new phosphodiesterase 4 inhibitor roflumilast is efficacious in exercise-induced asthma and leads to suppression of LPS-stimulated TNF-alpha ex vivo. J Clin Pharmacol. 2002;42:297–303. doi: 10.1177/00912700222011328.
    1. Bousquet J, Aubier M, Sastre J, Izquierdo JL, Adler LM, Hofbauer P, Rost KD, Harnest U, Kroemer B, Albrecht A, Bredenbröker D. Comparison of roflumilast, an oral anti-inflammatory, with beclomethasone dipropionate in the treatment of persistent asthma. Allergy. 2006;61:72–8.
    1. Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM. Effect of 1-Year Treatment with Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2007;176:154–61. doi: 10.1164/rccm.200610-1563OC.
    1. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, Bundschuh DS, Brose M, Martinez FJ, Rabe KF. M2-127 and M2-128 study groups. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet. 2009;374:695–703. doi: 10.1016/S0140-6736(09)61252-6.
    1. Calverley PM, Rabe KF, Goehring UM, Kristiansen S, Fabbri LM, Martinez FJ. M2-124 and M2-125 study groups. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009;374:685–94. doi: 10.1016/S0140-6736(09)61255-1.
    1. Knowles RG, Ball DI, Gascoigne MH, Tralau-Stewart C, Nials AT. In-vivo characterisation of GSK25 an exceptionally high affinity and selective PDE4 inhibitor suitable for topical administration. Am J Respir Crit Care Med. 2009;179:A4582.
    1. Singh SD, Richards D, Knowles RG, Schwartz S, Woodcock AA, Langley SJ, O'Connor BJ. Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma. Am J Respir Crit Care Med. 2007;176:988–93. doi: 10.1164/rccm.200704-588OC.
    1. Palmqvist M, Bruce C, Sjöstrand M, Arvidsson P, Lötvall J. Differential effects of fluticasone and. Allergy. 2005;60:65–70. doi: 10.1111/j.1398-9995.2005.00633.x.
    1. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet. 2007;370:1422–31. doi: 10.1016/S0140-6736(07)61600-6.
    1. Duong M, Gauvreau G, Watson R, Obminski G, Strinich T, Evans M, Howie K, Killian K, O'Byrne PM. The effects of inhaled budesonide and formoterol in combination and alone when given directly after allergen challenge. J Allergy Clin Immunol. 2007;119:322–7. doi: 10.1016/j.jaci.2006.10.018.
    1. Gauvreau GM, Boulet LP, Postma DS, Kawayama T, Watson RM, Duong M, Deschesnes F, De Monchy JG, O'Byrne PM. Effect of low-dose ciclesonide on allergen-induced responses in subjects with mild allergic asthma. J Allergy Clin Immunol. 2005;116:285–91. doi: 10.1016/j.jaci.2005.05.021.
    1. Inman MD, Watson RM, Rerecich T, Gauvreau GM, Lutsky BN, Stryszak P, O'Byrne PM. Dose-dependent effects of inhaled mometasone furoate on airway function and inflammation after allergen inhalation challenge. Am J Respir Crit Care Med. 2001;164:569–74.
    1. Virchow JC Jr, Walker C, Hafner D, Kortsik C, Werner P, Matthys H, Kroegel C. T cells and cytokines in bronchoalveolar lavage fluid after segmental allergen provocation in atopic asthma. Am J Respir Crit Care Med. 1995;151:960–8.
    1. Adcock IM, Ito K, Barnes PJ. Glucocorticoids. Effects on gene transcription. Proc Am Thorac Soc. 2004;1:247–254. doi: 10.1513/pats.200402-001MS.
    1. Peter D, Jin SL, Conti M, Hatzelmann A, Zitt C. Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D. J Immunol. 2007;178:4820–31.
    1. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med. 2005;352:2163–73. doi: 10.1056/NEJMoa043596.
    1. Kanniess F, Richter K, Böhme S, Jörres RA, Magnussen H. Montelukast versus fluticasone: effects on lung function, airway responsiveness and inflammation in moderate asthma. Eur Respir J. 2002;20:853–8. doi: 10.1183/09031936.02.00244602.
    1. Bethke TD, Böhmer GM, Hermann R, Hauns B, Fux R, Mörike K, David M, Knoerzer D, Wurst W, Gleiter CH. Dose-proportional intraindividual single- and repeated-dose pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor. J Clin Pharmacol. 2007;47:26–36. doi: 10.1177/0091270006294529.
    1. Vestbo J, Tan L, Atkinson G, Ward J. UK-500, 001 Global Study Team. A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD. Eur Respir J. 2009;33:1039–44. doi: 10.1183/09031936.00068908.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する